STVN
Overvalued by 149.4% based on the discounted cash flow analysis.
Market cap | $8.14 Billion |
---|---|
Enterprise Value | - |
Dividend Yield | $0.054 (0.2%) |
Earnings per Share | $0.0 |
Beta | 0.0 |
Outstanding Shares | 295,540,036 |
Avg 30 Day Volume | 347,909 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 0.0 |
---|---|
PEG | - |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | - |
Enterprise Value to Net Income | - |
Total Debt to Enterprise | - |
Debt to Equity | - |
No data
No data
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end por...